The genetic and clinical landscape of nanophthalmos in an Australian cohort

Running title: Genetics of nanophthalmos in Australia

Owen M Siggs¹, Mona S Awadalla¹, Emmanuelle Souzeau¹, Sandra E Staffieri^{2,3,4}, Lisa S Kearns², Kate Laurie¹, Abraham Kuot¹, Ayub Qassim¹, Thomas L Edwards², Michael A Coote², Erica Mancel⁵, Mark J Walland⁶, Joanne Dondey⁷, Anna Galanopoulos⁸, Robert J Casson⁸, Richard A Mills¹, Daniel G MacArthur^{9,10}, Jonathan B Ruddle^{2,3,4}, Kathryn P Burdon^{1,11}, Jamie E Craig¹

¹Department of Ophthalmology, Flinders University, Adelaide, Australia

²Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia

³Department of Ophthalmology, University of Melbourne, Melbourne, Australia

⁴Department of Ophthalmology, Royal Children's Hospital, Melbourne, Australia

⁵Centre Hospitalier Territorial de Nouvelle-Calédonie, Noumea, New Caledonia

⁶Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, Melbourne, Australia

⁷Royal Victorian Eye and Ear Hospital, Melbourne, Australia

⁸Discipline of Ophthalmology & Visual Sciences, University of Adelaide, Adelaide, Australia

⁹Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Boston, Massachusetts, USA

¹⁰Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA

¹¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Corresponding Author:

Owen M Siggs

Department of Ophthalmology, Flinders University, Bedford Park SA 5042, Australia

Phone: +61 8 8204 5062

Fax: +61 8 8277 0899

email: owen.siggs@flinders.edu.au

Keywords: microphthalmia, nanophthalmos, posterior microphthalmos, axial length, *PRSS56*, *MFRP*, *TMEM98*, *MYRF*.

Word Count (excluding title page, legends, and references): 3224

Abstract

Purpose: Refractive error is caused by a disparity between the axial length and focusing power of the eye. Nanophthalmos is a rare ocular abnormality in which both eyes are abnormally small, typically causing extreme hyperopic refractive error, and associated with an increased risk of angle-closure glaucoma.

Methods: A cohort of 40 individuals from 13 unrelated nanophthalmos kindreds were recruited, with 11 probands subjected to exome sequencing.

Results: Nine probands (69.2%) were assigned a genetic diagnosis, with variants in *PRSS56* (4), *MFRP* (3), and previously reported variants in *TMEM98* (1) and *MYRF* (1). Two of the four *PRSS56* probands harboured the previously described c.1066dupC frameshift variant implicated in over half of all reported *PRSS56* kindreds, with surrounding haplotypes distinct from each other, and from a previously reported Tunisian c.1066dupC haplotype. Individuals with a genetic diagnosis had shorter mean axial lengths ($P=7.22 \times 10^{-9}$) and more extreme hyperopia ($P=0.0005$) than those without a genetic diagnosis, with recessive forms associated with the shortest axial lengths and highest hyperopia. All individuals with an axial length below 18 mm in their smaller eye (17/17) were assigned a genetic diagnosis.

Conclusions: These findings detail the genetic architecture of nanophthalmos in an Australian cohort of predominantly European ancestry, their relative clinical phenotypes, and highlight the shared genetic architecture of rare and common disorders of refractive error.

Introduction

Clear vision requires precise regulation of ocular growth, such that the axial length of the eye matches the optical focal plane created by the cornea and lens. A discrepancy between the two results in refractive error, which is the leading cause of visual impairment and the second leading cause of blindness worldwide.¹ Refractive error may be termed either myopia (where the focal point is in front of the retina) or hyperopia (where it falls behind it). Both forms of refractive error are correctable, although individuals at the extremes of refractive error are at an increased risk of irreversible blindness due to associated complications such as myopic macular degeneration, retinal detachment, or primary open-angle glaucoma (in the case of myopia); or strabismus, amblyopia, retinal detachment and angle-closure glaucoma (in the case of hyperopia).²

Important insight into the developmental regulation of ocular axial length has come from the study of microphthalmia, which affects approximately 1 in 10,000 live births.³ Nanophthalmos and posterior microphthalmos are two rare subtypes of microphthalmia, both of which are associated with reduced axial length and high hyperopia.⁴ Posterior microphthalmos is characterised by reduced length of the posterior segment of the eye, with the anterior segment typically of normal length. Patients with posterior microphthalmos usually present with reduced visual acuity from an increase in the papillomacular retinal fold, occasional pigmentary retinopathy, and are susceptible to uveal effusions.^{5,6} Unlike posterior microphthalmos, nanophthalmos is characterized by a decrease in the size of both posterior and anterior segments, with a predisposition to primary angle-closure glaucoma.^{5,6} However, both posterior microphthalmos and nanophthalmos can be allelic⁷, supporting the hypothesis that they represent a continuum of the same phenotypic spectrum, rather than two distinct entities.⁸

Posterior microphthalmos and nanophthalmos are commonly inherited as autosomal recessive traits, with variants in two genes accounting for the majority of known cases. The first of these, *MFRP* (membrane frizzled-related protein), is expressed in retinal pigment epithelium and ciliary body, where a lack of *MFRP* disrupts emmetropization through an uncertain mechanism.^{9,10} Rare biallelic *MFRP* variants have been associated with nanophthalmos¹¹, isolated posterior microphthalmos⁷, and posterior microphthalmos with retinitis pigmentosa, foveoschisis, and optic disc drusen¹². Both *MFRP*-deficient mice¹³ and zebrafish¹⁴ have hyperopic phenotypes, consistent with a presumed loss-of-function mechanism in humans¹¹. Viral transduction of wild-type *Mfrp* into 5 day-old *Mfrp* mutant mice can also restore axial length¹³, suggesting that *MFRP* provides support for ocular development both *in utero* and after birth.

A second gene, *PRSS56* (protease, serine, 56), was initially identified in autosomal recessive nanophthalmos and posterior microphthalmos kindreds from the Faroe Islands, Tunisia, Canada, and Mexico.^{15–17} A chemically-induced mouse mutant at the orthologous locus showed close phenotypic parallels, with shortened axial length, hyperopia, and a propensity for angle closure.¹⁷ Recent work has shown that *PRSS56* is derived from late retinal progenitor cells or Müller glia, and promotes elongation of ocular axial length both before and after eye opening.¹⁸ *PRSS56* variants have also been implicated in multiple independent genome-wide association studies of myopia.^{19–21}

Autosomal dominant nanophthalmos is a less common clinical entity, and until recently only associated with variants in *TMEM98*^{22,23}. Like *PRSS56*, *TMEM98* has also been associated with myopia in a large genome-wide association study.²¹ A second dominant nanophthalmos locus, previously mapped to chromosome 11²⁴, has now been associated with variants in *MYRF*, which encodes a transcriptional regulator that drives expression of *TMEM98*.^{25–28}

Here we assembled a cohort of 40 individuals across 13 nanophthalmos kindreds, describe their underlying genetic cause, and detail the relative clinical presentations associated with each gene.

Methods

Subjects

Individuals with nanophthalmos were recruited through the Australian and New Zealand Registry of Advanced Glaucoma²⁹, and were included if they presented with bilateral and symmetrically small eyes, with an axial length less than 20 mm in both eyes. This threshold of 20 mm was previously shown to account for individuals below 3 standard deviations from the mean in the EPIC-Norfolk Eye Study, and proposed as a definition for nanophthalmos in the absence of any other standardised definition.³⁰ Exclusion criteria included unilateral disease, anterior segment coloboma, and multiple non-ophthalmic syndromic features. Angle closure glaucoma status was assessed in all participants, yet was not a criterion for inclusion. Ocular hypertension was defined as an intraocular pressure (IOP) above 21 mmHg, with glaucoma defined as a glaucomatous visual field defect with a corresponding neuroretinal rim thinning. Previously reported families with variants in *TMEM98* and *MYRF* were included in this cohort.^{23,28} Research followed the tenets of the Declaration of Helsinki with informed consent obtained from the subjects after explanation of the nature and possible consequences of the study. Ethics approval was granted by the Southern Adelaide Clinical Human Research Ethics Committee.

Sequencing

Exome sequencing and analysis was performed as previously described.³¹ Briefly, genomic DNA was extracted from venous blood samples using a QiaAmp DNA blood Maxi Kit (Qiagen), or from saliva using Oragene saliva DNA collection kits (DNA Genotek) according to the manufacturers' protocols. Exome capture was performed using the Agilent SureSelect system (v4 or v5) and paired-end libraries sequenced on an Illumina HiSeq (2000, 2500, or 4000). Read alignment and variant calling were performed according to GATK best practices for germline short variant discovery (<https://software.broadinstitute.org/gatk/>). Variant annotation was performed using Variant Effect Predictor, with population frequencies from gnomAD and Bravo/TOPMed freeze 5 collections.³² All putative causal variants were manually inspected in IGV. Capillary sequencing for *MFRP* or *PRSS56* was performed using primer sequences available upon request. RNAseq data was generated on tissues from 21 healthy donor eyes from 21 individuals as previously described.³³

Statistical analysis

Data were analysed with R (v3.6.1), with continuous variables displayed as mean $\pm$ SD (for normally distributed variables) or IQR (for non-normal variables), and categorical variables displayed as numbers and percentages. Mean values for axial length and spherical equivalent were calculated per individual using data from both eyes. *P* values were calculated by one-way ANOVA with Tukey multiple pairwise-comparison testing for normally distributed continuous variables, by Kruskal-Wallis test for non-normal continuous variables, or by Fisher's exact test for categorical variables. One-way between-group analysis of covariance was used to compare differences between groups adjusted by age.

Results

We recruited a total of 40 individuals with nanophthalmos from 13 families. The mean age at recruitment was 47.5 ± 20.7 years, 57.5% were female, and 69.2% of families were of self-reported European ancestry (European (9), mixed European/Indigenous Australian (1), Lebanese (1), Vietnamese (1), not reported (1)) (Figure 1A). Exome sequencing was performed on one or more affected individuals from each family, with the exception of family NNO03, in which a causative variant was identified by capillary sequencing. When including two previously reported pedigrees^{23,28}, a suspected genetic cause was identified in 9 of 13 kindreds (69.2%), in genes including *PRSS56* (4), *MFRP* (3), *TMEM98* (1), and *MYRF* (1) (Figure 1B, C, D, E). All variants were rare or absent in gnomAD, with CADD scores above 24, and recessive variants confirmed to be *in trans* by parental segregation testing (Table 1). Within tissues of dissected cadaveric human eyes³³, expression of the dominant genes *MYRF* and *TMEM98* was more similar to one another than to the recessive genes *MFRP* and *PRSS56* (Figure 1F).

Figure 1: Genetic characterisation of a nanophthalmos cohort.

(A) Self-reported ancestry of the 13 probands.

(B) Proportion of the cohort assigned likely pathogenic variants, and genes in which they occur.

(C) *PRSS56*- and *MFRP*-associated pedigrees. Square symbols, male; round symbols, female; diagonal line, deceased; black filled symbols, affected (nanophthalmos); unfilled symbols, unaffected; black arrow, proband; double horizontal line, consanguinity. Genotypes of affected individuals displayed alongside each family identifier.

(D) Schematic of the *PRSS56*, *MFRP*, *TMEM98*, and *MYRF* loci, indicating the location of variants identified in the current study. Filled boxes indicate coding sequence, asterisks indicate genes with variants from previously reported pedigrees.

(E) *PRSS56*, *MFRP*, *TMEM98*, and *MYRF* protein schematics, including domain structures and relative location of variants identified in the current study (white circles). Dashed vertical lines correspond to exon boundaries. C, cytoplasmic domain; TM, transmembrane domain; CUB, Complement C1r/C1s, Uegf, Bmp1 domain; L, LDL-receptor class A domain; FZ, frizzled domain; CC, coiled-coil domain.

(F) Relative mean expression (expressed as a log counts per kb per million mapped reads) of four known nanophthalmos genes (*TMEM98*, *MYRF*, *MFRP*, *PRSS56*) in dissected human adult cadaveric eye tissue. S, sclera; CS, corneal stroma; CE, corneal epithelium; TM, trabecular meshwork; DM, Descemet's membrane; ON, optic nerve; ONH, optic nerve head; PI, peripheral iris; CB, ciliary body.

We identified four predicted pathogenic variants in *MFRP* across three probands, including one nonsense variant previously associated with nanophthalmos (p.(Gln175Ter))¹¹, one splice site variant previously associated with retinitis pigmentosa (c.1124+1G>T)³⁴, and two missense variants with no previous disease associations (p.(Ala570Val) and p.(Gly503Val)) (Figure 1D,E).

Of the four probands with variants in *PRSS56*, all were found to have rare compound heterozygous or homozygous variants (Figure 1D,E, Table 1). These variants include previously unreported essential splice (c.849+1G>T and c.97+2dupT), frameshift (p.(Ala115GlyfsTer39)), and missense variants (p.(Arg564Cys)) predicted to be pathogenic, as well as two instances of the previously reported c.1066dupC frameshift variant. The *PRSS56* c.1066dupC frameshift insertion (also reported as c.1059_1066insC, or p.(Gln356ProfsTer152)), had previously been reported in multiple Tunisian families with posterior microphthalmos (Figure 2A).^{15,17,35} A more recent study revealed that a c.1066dupC variant found in multiple Tunisian families was derived from a common ancestor around 1,850 years earlier.³⁵ Another nine cases explained by the c.1066dupC variant have also been reported in a Saudi Arabian cohort of microphthalmia and posterior microphthalmos, accounting for 69% (9/13) of all cases with *PRSS56* variants in this report⁸, as well as in Egyptian and Lebanese patients.³⁶ It is not clear whether this was also due to a founder effect, although cohort ancestry (Saudi Arabian, Egyptian, and Lebanese) suggests that these cases were unlikely to share the Tunisian founder haplotype.

Table 1. Disease-associated gene variants in nine nanophthalmos probands. Genomic coordinates are based on the hg19 reference. AF, gnomAD r2.1.1 allele frequency; CADD, Phred-scaled CADD score. Variant consequences refer to the following transcript and protein accession IDs: *TMEM98* (ENST00000579849.1, ENSP00000463245.1), *PRSS56* (ENST00000617714.1, ENSP00000479745.1), *MFRP* (ENST00000555262.1, ENSP00000450509.1), *MYRF* (ENST00000278836.5, ENSP00000278836.4).

Family	gene	chr	start	ref	alt	state	class	cDNA	protein	AF	CADD
NNO03	<i>MFRP</i>	11	119214525	C	A	het	splice donor	c.1124+1G>T	.	0.00006065	26.4
NNO03	<i>MFRP</i>	11	119212289	G	A	het	missense	c.1709C>T	p.Ala570Val	0.000004098	24.4

NNO04	<i>MFRP</i>	11	119212574	C	A	het	missense	c.1508G>T	p.Gly503Val	.	25.6
NNO04	<i>MFRP</i>	11	119216248	G	A	het	stop gained	c.523C>T	p.Gln175Ter	0.00004022	36
NNO08	<i>MFRP</i>	11	119214525	C	A	hom	splice donor	c.1124+1G>T	.	0.00006065	26.4
NNO32	<i>MYRF</i>	11	61553331	C	-	het	frameshift deletion	c.3361del	p.Arg1121GlyfsTer36	.	.
NNO02	<i>PRSS56</i>	2	233387913	G	T	het	splice donor	c.849+1G>T	.	0.00008335	24.5
NNO02	<i>PRSS56</i>	2	233388527	-	C	het	frameshift insertion	c.1066dupC	p.Gln356ProfsTer152	0.0003668	.
NNO18	<i>PRSS56</i>	2	233388527	-	C	hom	frameshift insertion	c.1066dupC	p.Gln356ProfsTer152	0.0003668	.
NNO22	<i>PRSS56</i>	2	233385406	-	T	hom	splice donor	c.97+2dupT	.	.	.
NNO27	<i>PRSS56</i>	2	233386763	-	G	het	frameshift insertion	c.343dupG	p.Ala115GlyfsTer39	0.000009972	.
NNO27	<i>PRSS56</i>	2	233390091	C	T	het	missense	c.1690C>T	p.Arg564Cys	0.00001887	33
NNO01	<i>TMEM98</i>	17	31267907	G	C	het	missense	c.577G>C	p.Ala193Pro	.	29.5

221

222

223 To determine the origin of the c.1066dupC frameshift variant in our two Australian kindreds, we

224 compared surrounding haplotypes in NNO18, NNO02, and the previously described Tunisian

225 founder haplotype (Figure 2B).³⁵ Three phased variants were genotyped in both the NNO18

226 proband and the Tunisian founder (rs733602, rs2245601, and rs2767), yet the genotypes in

227 each were divergent, suggesting that the two alleles had arisen independently. Similarly, the

228 NNO02 haplotype included the C allele of rs2767 (compared to T in the Tunisian founder),

229 suggesting that the c.1066dupC variant in NNO02 was also unlikely to have come from the

230 Tunisian founder. To compare the origins of the *PRSS56* haplotypes in NNO02 and NNO18, we

231 made use of a closely linked variant (rs79792358) in *PRSS56* (149 bp downstream of

232 c.1066dupC). This variant and the c.1066dupC insertion were both present in the NNO02

233 proband but absent from the NNO18 proband, suggesting that the NNO02 and NNO18

234 frameshift variants arose independently on different haplotypes (Figure 2B).

235

Figure 2: The origins of PRSS56 c.1066dupC in a mutational hotspot.

(A) Schematic of the PRSS56 protein, including domain structures and the relative location of variants identified in the current study (white circles), or in previous reports (coloured circles). Dashed vertical lines correspond to exon boundaries.

(B) Comparative haplotype structure surrounding the PRSS56 c.1066dupC variant in the previously reported Tunisian founder, and two unrelated probands reported here (NNO18, NNO02).

(C) Frequency of PRSS56 loss-of-function variants (nonsense, essential splice, frameshift) reported in the gnomAD r2.0.2 and Bravo (TOPMed Freeze5) collections. The c.1066dupC variant is highlighted in red.

(D) Allele frequency of the c.1066dupC variant across multiple ancestries within gnomAD r2.0.2.

(E) IGV representation of the left-shifted c.1066dupC variant in the context of the cytosine mononucleotide repeat.

The c.1066dupC frameshift insertion was the most frequent loss-of-function PRSS56 variant in the gnomAD collection of genomes and exomes (Figure 2C), representing over half (58/112) of all reported PRSS56 loss-of-function variants. These 58 c.1066dupC variants were distributed across seven ancestral populations at allele frequencies between 2.5×10^{-4} and 6.9×10^{-4} , consistent with the independent emergence of c.1066dupC variants in multiple populations (Figure 2D). PRSS56 c.1066 was also noted to be a multiallelic site, with insertions and deletions reported at the same position (Figure 2C), both of which altered the length of an eight nucleotide cytosine mononucleotide repeat (Figure 2E).

Figure 3: Genetic diagnosis is associated with shorter axial lengths and increased hyperopia.

Ocular axial length (A) and spherical equivalent (B) of affected family members stratified by genetic diagnosis. Mean values were calculated per individual using data from both eyes. For both comparisons, group means were significantly different by one-way ANOVA ($P < 0.0003$), with asterisks (*) indicating a significant difference from the unsolved cohort (Tukey multiple comparison testing, $P < 0.003$).

Individuals with suspected pathogenic variants in *PRSS56*, *MFRP*, *TMEM98*, or *MYRF* had reduced ocular axial length (Figure 3A, Table 2), with the majority also highly hyperopic (Figure 3B, Table 2). The mean axial length was significantly shorter in groups with a genetic diagnosis compared to those without ($P = 7.22 \times 10^{-9}$), with the *PRSS56* subset also having a shorter mean axial length than the dominant *TMEM98* (adjusted $P = 0.00003$) and *MYRF* (adjusted $P = 0.00004$) subsets (Figure 3A). All groups also had a significantly higher mean refractive error ($P = 0.0005$), with *PRSS56* and *MFRP* groups more hyperopic than nanophthalmic individuals without a genetic diagnosis (Figure 3B, Table 2). Across the entire cohort and in those where data were available, 22.6% (7/31) had glaucoma, and 43.3% (13/30) had a pressure-lowering surgical intervention in at least one eye (laser peripheral iridotomy, selective laser trabeculoplasty, or trabeculectomy). Neither of these variables showed a significant difference between the genetic diagnosis groups ($P = 0.6665$ and $P = 1.0000$ respectively), even after adjusting for age at recruitment (Table 2).

Table 2. Summary of genotype-phenotype correlates. Continuous variables are displayed as mean $\pm$ SD (for normally distributed variables) or IQR (for non-normal variables), with categorical variables displayed as numbers and percentages. *P* values were calculated by one-way ANOVA for normally distributed variables, Kruskal-Wallis test for non-normal continuous variables, or by Fisher's exact test for categorical variables. AL, axial length; AC, anterior chamber; SE, spherical equivalent; MD, mean deviation; SD, standard deviation; IQR, interquartile range.

	Unsolved	<i>MYRF</i>	<i>TMEM98</i>	<i>MFRP</i>	<i>PRSS56</i>	<i>P</i>
n	6	5	16	4	9	
Gender = F/M (%)	5/1 (83.3/16.7)	2/3 (40.0/60.0)	7/9 (43.8/56.2)	4/0 (100.0/0.0)	5/4 (55.6/44.4)	0.1937
Age at recruitment (mean (SD))	56.83 (11.27)	28.40 (20.21)	51.38 (22.43)	55.50 (9.75)	34.67 (17.34)	0.033
AL (mean (SD))	19.27 (0.52)	18.01 (0.31)	17.66 (0.62)	16.44 (0.64)	15.76 (0.74)	<0.0001
SE (mean (SD))	9.04 (0.83)	9.38 (3.64)	11.79 (2.43)	15.62 (2.33)	14.77 (3.66)	0.0005
Maximum IOP (median [IQR])	19.00 [16.25, 22.50]	16.00 [13.50, 21.00]	19.00 [17.00, 28.00]	23.00 [20.00, 27.75]	16.50 [15.00, 24.25]	0.6016
Glaucoma = No/Yes (%)	5/1 (83.3/16.7)	4/0 (100.0/0.0)	6/4 (60.0/40.0)	3/1 (75.0/25.0)	6/1 (85.7/14.3)	0.6665
IOP intervention = FALSE/TRUE (%)	3/3 (50.0/50.0)	2/2 (50.0/50.0)	6/4 (60.0/40.0)	2/2 (50.0/50.0)	4/2 (66.7/33.3)	1

Discussion

Here we described an Australian nanophthalmos cohort of predominantly European ancestry in which 53.8% (7/13) of families were explained by variants in *MFRP* or *PRSS56*, or 69.2% (9/13) when including previously reported families with variants in *TMEM98* or *MYRF*.^{23,28} Mean axial length was shorter in all four groups of individuals with a genetic diagnosis compared to those without, with the recessive *PRSS56* and *MFRP* forms associated with the shortest axial length. Similarly, hyperopia was higher in affected individuals with a known genetic diagnosis compared to those without. This suggests that individuals with milder nanophthalmos phenotypes may be explained by variants in other genes, and emphasises the importance of prioritising genetic testing for *MFRP* and *PRSS56* in individuals with the most severe nanophthalmos phenotypes.

All individuals with an axial length below 18 mm in their smaller eye had a genetic diagnosis (17/17), with all but one under 17 mm associated with variants in either *PRSS56* or *MFRP*

(10/11). Previous population studies have shown these thresholds to capture 0.137% (<18 mm) and 0.05% (<17 mm) of an adult British population³⁰, and we propose that these be considered a threshold for identifying an underlying single gene cause.

PRSS56 was the most commonly implicated gene in this cohort (4/13, 30.8%) and in other cohorts of posterior microphthalmos and nanophthalmos (27.3% - 61.5%).^{8,26,36} Including the four described here, at least 32 pedigrees have been described with *PRSS56*-associated posterior microphthalmos or nanophthalmos.^{8,15–17,26,35,36} Twenty of these pedigrees (62.5%) share the same c.1066dupC frameshift insertion variant, or 55.6% (15/27) if one considers the six Tunisian pedigrees with a shared haplotype as a single extended pedigree.^{17,35} Two of the families reported here harbour the c.1066dupC variant on at least one allele, which lay on haplotypes distinct from each other and from the previously reported Tunisian pedigree, suggesting the existence of a mutational hotspot in *PRSS56*. These variants arose in the context of an eight nucleotide cytosine mononucleotide repeat, which is incidentally a frequent occurrence in *MYRF*-associated nanophthalmos and high hyperopia²⁸, and is likely secondary to slipped-strand mispairing during DNA replication.³⁷

While loss-of-function variants such as *PRSS56*:c.1066dupC are associated with reduced axial length and hyperopia, variants that enhance the activity of *PRSS56* might be expected to lead to increased axial length and myopia. The p.(Ala30Thr) variant of *PRSS56* is one of the few protein-coding variants to have emerged from genome-wide association studies of refractive error. Unlike the loss-of-function variants described here which associate with hyperopia, p.(Ala30Thr) is associated with myopia, suggesting that it may increase axial length through a gain-of-function mechanism.²⁰ *PRSS56* itself is a soluble serine protease, potentially sensitive to protease inhibitors or monoclonal antibodies, and therefore would be a candidate therapeutic target in the treatment of refractive error. It has already been shown that deletion of *Prss56* can

reduce axial length and correct refractive error in an *Egr1* mutant mouse model of myopia¹⁸, raising the possibility that PRSS56 inhibitors might be applied to the treatment of myopia in humans.

In summary, we present the genetic landscape of nanophthalmos in an Australian cohort, revealing a considerable overlap between genes associated with rare and common refractive error phenotypes. The shortest axial length and most extreme hyperopic refractive error were associated with autosomal recessive forms of nanophthalmos (*PRSS56* and *MFRP*), with a less extreme phenotype in autosomal dominant forms (*TMEM98* and *MYRF*). Finally, we demonstrated that the most frequent single variant associated with nanophthalmos across all ancestries, *PRSS56* c.1066dupC, is likely to have arisen independently in at least four different populations, highlighting the importance of a single mutational hotspot in the global prevalence of nanophthalmos.

Acknowledgments

Supported by grants from the National Health and Medical Research Council (NHMRC APP1107098), the Ophthalmic Research Institute of Australia, and Flinders University. KPB was funded by an NHMRC Career Development Award, and JEC by an NHMRC Practitioner Fellowship. DGM was supported in part by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900, and by the National Human Genome Research Institute grant R01 HG009141.

Competing Interests Statement

The authors report no conflicts of interest.

References

1. Bourne RRA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. *Lancet Glob Health*. 2013;1(6):e339-e349.
2. Verhoeven VJM, Wong KT, Buitendijk GHS, Hofman A, Vingerling JR, Klaver CCW. Visual consequences of refractive errors in the general population. *Ophthalmology*. 2015;122(1):101-109.
3. Dharmasena A, Keenan T, Goldacre R, Hall N, Goldacre MJ. Trends over time in the incidence of congenital anophthalmia, microphthalmia and orbital malformation in England: database study. *Br J Ophthalmol*. 2017;101(6):735-739.
4. Källén B, Robert E, Harris J. The descriptive epidemiology of anophthalmia and microphthalmia. *Int J Epidemiol*. 1996;25(5):1009-1016.
5. Khan AO. Recognizing posterior microphthalmos. *Ophthalmology*. 2006;113(4):718.
6. Khan AO. Posterior microphthalmos versus nanophthalmos. *Ophthalmic Genet*. 2008;29(4):189.
7. Aldahmesh MA, Nowilaty SR, Alzahrani F, et al. Posterior microphthalmos as a genetically heterogeneous condition that can be allelic to nanophthalmos. *Arch Ophthalmol*. 2011;129(6):805-807.
8. Nowilaty SR, Khan AO, Aldahmesh MA, Tabbara KF, Al-Amri A, Alkuraya FS. Biometric and molecular characterization of clinically diagnosed posterior microphthalmos. *Am J Ophthalmol*. 2013;155(2):361-372.e7.
9. Mandal MNA, Vasireddy V, Jablonski MM, et al. Spatial and temporal expression of MFRP and its interaction with CTRP5. *Invest Ophthalmol Vis Sci*. 2006;47(12):5514-5521.
10. Sundin OH, Dharmaraj S, Bhutto IA, et al. Developmental basis of nanophthalmos: MFRP is required for both prenatal ocular growth and postnatal emmetropization. *Ophthalmic Genet*. 2008;29(1):1-9.
11. Sundin OH, Leppert GS, Silva ED, et al. Extreme hyperopia is the result of null mutations in MFRP, which encodes a Frizzled-related protein. *Proc Natl Acad Sci U S A*. 2005;102(27):9553-9558.
12. Crespi J, Buil JA, Bassaganyas F, et al. A novel mutation confirms MFRP as the gene causing the syndrome of nanophthalmos-renalitis pigmentosa-foveoschisis-optic disk drusen. *Am J Ophthalmol*. 2008;146(2):323-328.
13. Velez G, Tsang SH, Tsai Y-T, et al. Gene Therapy Restores Mfrp and Corrects Axial Eye Length. *Sci Rep*. 2017;7(1):16151.
14. Collery RF, Volberding PJ, Bostrom JR, Link BA, Besharse JC. Loss of Zebrafish Mfrp Causes Nanophthalmia, Hyperopia, and Accumulation of Subretinal Macrophages. *Invest Ophthalmol Vis Sci*. 2016;57(15):6805-6814.
15. Gal A, Rau I, El Matri L, et al. Autosomal-recessive posterior microphthalmos is caused by mutations in PRSS56, a gene encoding a trypsin-like serine protease. *Am J Hum Genet*.

- 391 2011;88(3):382-390.
- 392 16. Orr A, Dubé M-P, Zenteno JC, et al. Mutations in a novel serine protease PRSS56 in
393 families with nanophthalmos. *Mol Vis*. 2011;17:1850-1861.
- 394 17. Nair KS, Hmani-Aifa M, Ali Z, et al. Alteration of the serine protease PRSS56 causes angle-
395 closure glaucoma in mice and posterior microphthalmia in humans and mice. *Nat Genet*.
396 2011;43(6):579-584.
- 397 18. Paylakhi S, Labelle-Dumais C, Tolman NG, et al. Müller glia-derived PRSS56 is required to
398 sustain ocular axial growth and prevent refractive error. *PLoS Genet*. 2018;14(3):e1007244.
- 399 19. Verhoeven VJM, Hysi PG, Wojciechowski R, et al. Genome-wide meta-analyses of
400 multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia.
401 *Nat Genet*. 2013;45(3):314-318.
- 402 20. Kiefer AK, Tung JY, Do CB, et al. Genome-wide analysis points to roles for extracellular
403 matrix remodeling, the visual cycle, and neuronal development in myopia. *PLoS Genet*.
404 2013;9(2):e1003299.
- 405 21. Tedja MS, Wojciechowski R, Hysi PG, et al. Genome-wide association meta-analysis
406 highlights light-induced signaling as a driver for refractive error. *Nat Genet*. 2018;50(6):834-
407 848.
- 408 22. Khorram D, Choi M, Roos BR, et al. Novel TMEM98 mutations in pedigrees with autosomal
409 dominant nanophthalmos. *Mol Vis*. 2015;21:1017-1023.
- 410 23. Awadalla MS, Burdon KP, Souzeau E, et al. Mutation in TMEM98 in a Large White Kindred
411 With Autosomal Dominant Nanophthalmos Linked to 17p12-q12. *JAMA Ophthalmol*.
412 2014;132(8):970.
- 413 24. Othman MI, Sullivan SA, Skuta GL, et al. Autosomal dominant nanophthalmos (NNO1) with
414 high hyperopia and angle-closure glaucoma maps to chromosome 11. *Am J Hum Genet*.
415 1998;63(5):1411-1418.
- 416 25. Garnai SJ, Brinkmeier ML, Emery B, et al. Variants in myelin regulatory factor (MYRF)
417 cause autosomal dominant and syndromic nanophthalmos in humans and retinal
418 degeneration in mice. *PLoS Genet*. 2019;15(5):e1008130.
- 419 26. Guo C, Zhao Z, Chen D, et al. Detection of Clinically Relevant Genetic Variants in Chinese
420 Patients With Nanophthalmos by Trio-Based Whole-Genome Sequencing Study. *Invest*
421 *Ophthalmol Vis Sci*. 2019;60(8):2904-2913.
- 422 27. Xiao X, Sun W, Ouyang J, et al. Novel truncation mutations in MYRF cause autosomal
423 dominant high hyperopia mapped to 11p12-q13.3. *Hum Genet*. June 2019.
424 doi:10.1007/s00439-019-02039-z
- 425 28. Siggs OM, Souzeau E, Breen J, et al. Autosomal dominant nanophthalmos and high
426 hyperopia associated with a C-terminal frameshift variant in. *Mol Vis*. 2019;25:527-534.
- 427 29. Souzeau E, Goldberg I, Healey PR, et al. Australian and New Zealand Registry of
428 Advanced Glaucoma: methodology and recruitment. *Clin Experiment Ophthalmol*.
429 2012;40(6):569-575.

30. Day AC, Khawaja AP, Peto T, et al. The small eye phenotype in the EPIC-Norfolk eye study: prevalence and visual impairment in microphthalmos and nanophthalmos. *BMJ Open*. 2013;3(7):e003280. doi:10.1136/bmjopen-2013-003280
31. Siggs OM, Souzeau E, Pasutto F, et al. Prevalence of FOXC1 Variants in Individuals With a Suspected Diagnosis of Primary Congenital Glaucoma. *JAMA Ophthalmol*. January 2019. doi:10.1001/jamaophthalmol.2018.5646
32. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. *Genomics*. January 2019:806.
33. Siggs OM, Souzeau E, Taranath DA, et al. Congenital glaucoma with anterior segment dysgenesis in individuals with biallelic CPAMD8 variants. doi:10.1101/297077
34. Dinculescu A, Estreicher J, Zenteno JC, et al. Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept. *Hum Gene Ther*. 2012;23(4):367-376.
35. Said MB, Chouchène E, Salem SB, et al. Posterior microphthalmia and nanophthalmia in Tunisia caused by a founder c.1059_1066insC mutation of the PRSS56 gene. *Gene*. 2013;528(2):288-294.
36. Patel N, Khan AO, Alsahli S, et al. Genetic investigation of 93 families with microphthalmia or posterior microphthalmos. *Clin Genet*. 2018;93(6):1210-1222.
37. Levinson G, Gutman GA. Slipped-strand mispairing: a major mechanism for DNA sequence evolution. *Mol Biol Evol*. 1987;4(3):203-221.